| Returns | 1W : 0.7% , 1M : 3.1%,1Y : 59.1% |
| Peers & Returns | 1W | 1M | 1Y |
| SHILPA MEDICARE LTD | 0.7% | 3.1% | 59.1% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | -2.1% | 7.7% | 32.6% |
| DR REDDYS LABORATORIES LTD | -4.4% | 0.3% | 66.4% |
| DIVIS LABORATORIES LTD | -3.2% | -0.7% | 90.1% |
| CIPLA LTD | -0.9% | 7% | 71.3% |
| BIOCON LTD | -3.7% | -0.2% | 54.7% |
| AUROBINDO PHARMA LTD | -3.1% | 10% | 91.3% |
| LUPIN LTD | -1.7% | 16.9% | 48.8% |
| TORRENT PHARMACEUTICALS LTD | -2.4% | 2.1% | 35.6% |
| Ratio | Value |
|---|---|
|
P/E P/B P/S |
22.97
P/E Calculated based on EPS of 19.15
[ Mar2020 - Consolidated Results ] 2.7
P/B Calculated based on Book Value of 163.06
[ Mar2020 - Consolidated Results ] 3.7
P/S Calculated based on Revenues of 969.626 Cr
[ TTM - Consolidated Results ] |
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
34% 23% 39% |
| Year | Debt/Equity ratio | |
|---|---|---|
|
Debt/Equity ratio analysis
For all non-Banking industries, Good = Ratio less than 0.4 Average = Ratio between 0.4 and 0.6 Bad = Ratio greater than 0.6 Worst is considered between Standalone & Consolidated |
Standalone | Consolidated |
|
2020 2019 2018 Avg_3yrs |
0.26 0.15 0.16 0.19 |
0.29 0.16 0.18 0.21 |
|
[Last Annual Data : Mar2020]
|
||
| Pledged Shares |
0.81 % |
|---|---|
| As on : Sep2020 | |
If less than 25% | Good |
| If between 25% and 50% | Neutral |
| If greater than 50% | Bad |
| Consolidated | 1 Qtr Growth | 4 Qtr Growth |
|---|---|---|
|
Revenue Op Profit EBIDT Net Income |
25.16% 9.34% -47.09% -47.76% |
-3.79% 5.5% -1.78% -11.57% |
| QtrlyTrend |
-2
Quarterly Trend analysis
The growth rate score are assigned as under: If ratio's 1Q growth is +ve, then 1. If -ve, then -1. If ratio's 4Q growth is +ve, then 1.If -ve, then -1. Growth Score= Sum of all the above scores for Revenue, Operating Profit and Net Income. Interpretation Good = Growth Score >=4 Neutral = Growth Score between 0 and 4 Bad = Growth Score less than 0 |
|
| Latest Qtr: Sep2020 | ||
